<div><div></div><div><span><p><span>Mardi Dier, EVP and CFO of MADRIGAL PHARMACEUTICALS, sold 1,183 shares of Common Stock on March 2, 2026, at a price of $427.21 per share, totaling $505,389. This sale was to cover tax withholding obligations related to the vesting of restricted stock units. Following this transaction, Dier directly owns 9,257 shares of MADRIGAL PHARMACEUTICALS.</span></p><div><table><tbody><tr><td><span>Reporter Name</span></td><td><span>Dier Mardi</span></td></tr><tr><td><span>Relationship</span></td><td><span>EVP and CFO</span></td></tr><tr><td><span>Type</span></td><td><span>Sell</span></td></tr><tr><td><span>Amount</span></td><td><span>$505,389</span></td></tr><tr><td><span>SEC Filing</span></td><td>Form 4</td></tr></tbody></table></div><p><span>SEC Filing: </span>MADRIGAL PHARMACEUTICALS, INC. [ MDGL ] - Form 4 - Mar. 02, 2026</p><section><b><span class="heading-aHOVUrmQ">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

ARKG

<p>Mardi Dier, EVP and CFO of Madrigal Pharmaceuticals, sold 1,183 shares of Common Stock on March 2, 2026, for $505,389 to cover tax obligations from restricted stock units. After the sale, Dier retains 9,257 shares of the company.</p>

TradingView

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

Madrigal Pharma

SPDR S&P Biotech

iShares Biotechnology ETF

iShares US Pharma

iShares Global Healthcare

VG Health

Health Care Select Sector SPDR

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

MADRIGAL PHARMACEUTICALS EVP and CFO Sells Shares to Cover Tax Obligations